{"organizations": [], "uuid": "2afcc8850049d8106a8d86cfc61680d13576af8f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/09/business-wire-pasha-sarraf-m-d-ph-d-joins-leerink-partners-equity-research-team.html", "country": "US", "domain_rank": 767, "title": "Pasha Sarraf, M.D., Ph.D. Joins Leerink Partners Equity Research Team", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.993, "site_type": "news", "published": "2018-05-09T17:00:00.000+03:00", "replies_count": 0, "uuid": "2afcc8850049d8106a8d86cfc61680d13576af8f"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/09/business-wire-pasha-sarraf-m-d-ph-d-joins-leerink-partners-equity-research-team.html", "ord_in_thread": 0, "title": "Pasha Sarraf, M.D., Ph.D. Joins Leerink Partners Equity Research Team", "locations": [], "entities": {"persons": [{"name": "pasha sarraf", "sentiment": "neutral"}, {"name": "sarraf", "sentiment": "none"}, {"name": "pasha", "sentiment": "none"}], "locations": [{"name": "boston", "sentiment": "none"}, {"name": "new york", "sentiment": "none"}, {"name": "massachusetts", "sentiment": "none"}], "organizations": [{"name": "leerink partners equity research team leerink partners", "sentiment": "negative"}, {"name": "therapeutics research", "sentiment": "none"}, {"name": "mckinsey", "sentiment": "none"}, {"name": "harvard medical school", "sentiment": "none"}, {"name": "leerink partners", "sentiment": "none"}, {"name": "senior research analyst", "sentiment": "none"}, {"name": "national institutes of health", "sentiment": "none"}, {"name": "nih", "sentiment": "none"}, {"name": "global pharmaceuticals", "sentiment": "none"}, {"name": "mckinsey center for asset optimization", "sentiment": "none"}, {"name": "mckinsey & company", "sentiment": "none"}, {"name": "mgh", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Leerink Partners takes an innovative approach to expanding the Therapeutics team\nBOSTON--(BUSINESS WIRE)-- Leerink Partners, a leading healthcare investment bank, announced today that Pasha Sarraf, M.D., Ph.D. has joined the Therapeutics Research team as a Senior Research Analyst based in the firm’s New York office. Dr. Sarraf will cover biopharmaceutical companies developing and marketing products for inflammatory and immunological diseases and will also lead the firm’s research efforts in other therapeutic areas.\nDr. Sarraf joins Leerink Partners from McKinsey & Company where he was a Partner and co-leader in the Global Pharmaceuticals practice as well as a leader of the McKinsey Center for Asset Optimization. In addition to his 10 year career at McKinsey, Pasha spent seventeen years as a Physician-Scientist where he trained at Harvard Medical School, Massachusetts General Hospital (MGH) and the National Institutes of Health (NIH). Dr. Sarraf completed his residency in internal medicine at MGH, and then completed fellowships in rheumatology at MGH and in rare diseases at NIH. Dr. Sarraf earned a M.D. and Ph.D. in cell and molecular biology from Harvard University and a B.S.E. magna com laude in biomedical engineering from Duke University.\nIn addition to Dr. Sarraf’s extensive personal, industry and professional experience, he has had a successful research career, having published over 40 articles and chapters in journals and textbooks, including articles in Nature Medicine, Molecular Cell and Science as well as in standard medical texts.\nLeerink Partners has a demonstrated history of delivering unique and valuable insights to investors across every sector of healthcare. These insights come from expertise and talent from all parts of the industry, not solely traditional Wall Street voices and sources.\n“We are excited to have Pasha join the firm as we continue our pursuit to build the best healthcare research team in the industry,” stated Jeff Leerink, Chairman and CEO of Leerink Partners. “We aim to provide the deepest and most comprehensive research available for our corporate and investor clients.”\nJohn Sullivan, Director of Research and Healthcare Investment Strategist at Leerink Partners stated, “Rooted in our commitment to build a preeminent Equity Research team is our belief that depth and breadth don’t just come from career analysts, but from bringing together a group of talented individuals with a mixture of skills and backgrounds. Pasha’s extensive experience working with senior biopharma management teams will add a unique voice to equity research regarding the industry.”\nGeoffrey Porges, Director of Therapeutics at Leerink Partners added, “The biopharmaceutical industry is becoming more complex and more dynamic every day. Therapeutics equity research must keep up with these changes and, with Pasha’s industry, clinical and scientific expertise, we are confident we can bring the very best and most insightful research around developments in important disease areas to our clients.”\n“I am honored and delighted to join Leerink Partners. The firm has a built an outstanding team of professionals who bring distinctive insights to clients and are elevating the thinking in healthcare investing and research,” stated Dr. Sarraf. “Together, with the entire research team, I look forward to serving the many investors and clients who are enabling the current wave of innovation in therapeutics.”\nAbout Leerink Partners\nLeerink Partners LLC is a leading investment bank, specializing in healthcare. Our knowledge, experience and focus enable us to help our clients define and achieve their strategic, capital markets and investment objectives. We partner with companies that develop and commercialize innovative products and services that are defining the future of healthcare. Leerink Partners LLC is a member of FINRA/SIPC. For more information, please visit: www.leerink.com .\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180509005033/en/\nLeerink Partners\nDiane Vieira, 617-918-4097\nor\nWeber Shandwick\n617-520-7088\nSource: Leerink Partners", "external_links": ["https://www.businesswire.com/news/home/20180509005033/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.leerink.com&esheet=51802428&newsitemid=20180509005033&lan=en-US&anchor=www.leerink.com&index=1&md5=1190e797e2bf4a90e159e8a8e2804398"], "published": "2018-05-09T17:00:00.000+03:00", "crawled": "2018-05-09T18:46:03.000+03:00", "highlightTitle": ""}